Who makes Low-flow medical oxygen insufflation?

Low-flow medical oxygen insufflation is developed by Outcomes'10.

What development phase is Low-flow medical oxygen insufflation in?

Low-flow medical oxygen insufflation is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Low-flow medical oxygen insufflation

Outcomes'10 · FDA-approved active Small molecule Quality 0/100

Low-flow medical oxygen insufflation, marketed by Outcomes'10, holds a position in the respiratory therapy segment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the 2028 patent expiry.

At a glance

Generic name	Low-flow medical oxygen insufflation
Sponsor	Outcomes'10
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Usefulness of High-flow Oxygen Therapy of Patients at Risk of Hypoxemia Undergoing Digestive Endoscopy Under Deep Sedation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low-flow medical oxygen insufflation CI brief — competitive landscape report
Low-flow medical oxygen insufflation updates RSS · CI watch RSS
Outcomes'10 portfolio CI